10-K: Oragenics Advances Brain Injury Drug Amidst Going Concern

Oragenics, Inc. reports continued operating losses and a going concern doubt, while advancing its lead mild traumatic brain injury drug candidate, ONP-002, into Phase 2a clinical trials in Q1 2026.

Summary

• Oragenics is a development-stage biopharmaceutical company focused on nasal delivery pharmaceutical therapies for neurological conditions and infectious diseases.
• The company's lead product candidate, ONP-002, is a fully synthetic neurosteroid targeting mild traumatic brain injury (mTBI or Concussion).
• Pre-clinical animal studies for ONP-002 are complete, demonstrating a large safety margin, rapid brain biodistribution, reduction in swelling, inflammation, and oxidative stress, and positive behavioral outcomes.
• A Phase 1 clinical trial in healthy human subjects for ONP-002 has been completed in Australia, showing the drug is safe and well-tolerated.
• The company anticipates launching Phase 2a clinical trials for ONP-002 in Australia in the first quarter of 2026.
• Oragenics incurred a net loss of $9.8 million for the year ended December 31, 2025, compared to $10.6 million in 2024.
• As of December 31, 2025, the company had an accumulated deficit of approximately $226.6 million.
• Cash and cash equivalents totaled $8.4 million as of December 31, 2025.
• Management anticipates being able to fund operating expenses and capital expenditure requirements through the third quarter of 2026, but will require additional capital beyond that period.
• The company's independent registered public accounting firm has included an explanatory paragraph in its audit report expressing substantial doubt about its ability to continue as a going concern.
• A 1-for-30 reverse stock split of outstanding common stock was effected on June 3, 2025.
• In July 2025, the company completed a public offering of Series H Convertible Preferred Stock and warrants, resulting in approximately $15 million in net proceeds.
• The conversion price of the Series H Preferred Stock was reduced to $1.00 per share effective March 14, 2026, due to the issuance of common stock at that price for advisory fees.
• The company settled litigation with Ladenburg Thalmann & Co. Inc. for $700,000 in October 2025, resolving a dispute over a $2.5 million fee.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk, early-stage biopharmaceutical company facing significant financial challenges and a going concern doubt, despite some positive preclinical and Phase 1 clinical trial results for its lead candidate. The substantial dilution from recent financing and the persistent need for further capital raises indicate a precarious financial position.

Positives

• ONP-002 has successfully completed Phase 1 clinical trials in healthy human subjects, demonstrating safety and tolerability.
• Pre-clinical animal studies for ONP-002 showed a large safety margin, rapid and broad biodistribution throughout the brain, and a reduction in swelling, inflammation, and oxidative stress, with positive behavioral outcomes.
• ONP-002 has demonstrated stability up to 104 degrees for 18 months, indicating a robust drug candidate.
• The company has been granted national patents for C-20 steroid compounds in 9 countries, including European countries, Canada, and the Philippines, with a U.S. patent potentially extending to 2040.
• Multiple patent applications for the Breath-Powered Nasal Devices have been filed in the U.S. and over 60 countries, with an exemplary U.S. patent expiration in 2042.
• A financing transaction in July 2025 provided approximately $15 million in net proceeds, improving the company's liquidity position.
• The company successfully settled litigation with Ladenburg Thalmann & Co. Inc. for $700,000, resolving a $2.5 million claim.

Negatives

• The company has incurred significant net losses ($9.8 million in 2025) and negative cash flows from operations since its inception, with an accumulated deficit of $226.6 million as of December 31, 2025.
• The independent registered public accounting firm has included an explanatory paragraph in its audit report expressing substantial doubt about the company's ability to continue as a going concern.
• Current cash resources are only anticipated to fund operating expenses through the third quarter of 2026, necessitating additional capital raises.
• The Series H Preferred Stock contains anti-dilution provisions that can lead to significant dilution for existing common shareholders if future securities are issued below the conversion price.
• The conversion price of the Series H Preferred Stock was already reduced from $2.50 to $1.00 per share effective March 14, 2026, due to common stock issuance at $1.00, indicating prior dilution.
• The company is heavily dependent on outside scientists and third-party research institutions for its research and development activities.
• The company relies on sole-source third-party manufacturers for ONP-002 drug product and substance, posing supply chain risks.
• COVID vaccine and lantibiotics programs have been paused due to limited capital, which may lead to breaches of license agreements and an inability to develop these candidates in the future.
• The market opportunities for ONP-002 may be smaller than currently believed, or alternative drugs/technologies could be adopted before regulatory approval.
• The company has limited neurology-specific research, development, manufacturing, testing, regulatory, commercialization, sales, distribution, and marketing experience.
• The market price of the company's common stock has been highly volatile, with a 52-week range of $0.75 to $12.30, and a closing price of $0.88 as of March 13, 2026.
• The company does not intend to pay cash dividends in the foreseeable future.

Risks

• Incurred significant operating losses since inception and cannot assure generation of revenues or profitability.
• Need to raise additional capital to continue business strategy and may not be able to do so.
• Ability to obtain funding (non-dilutive or otherwise) for research, development, manufacture, and commercialization of product candidates.
• Ability to maintain compliance with NYSE American continued listing requirements.
• Timing, progress, and results of clinical trials of product candidates.
• Uncertainties regarding submission, approval, and scope of filings for regulatory approval of product candidates.
• Uncertainties regarding potential benefits, activity, effectiveness, and safety of product candidates.
• Uncertainties regarding the size of patient populations, market acceptance, and opportunity for clinical utility of product candidates.
• Manufacturing capabilities and strategy, including scalability and commercial viability.
• Ability to successfully commercialize product candidates.
• Uncertainties regarding expenses, ongoing losses, future revenue, and capital requirements.
• Ability to identify, recruit, and retain key personnel and consultants.
• Ability to obtain, retain, protect, and enforce intellectual property position.
• Ability to advance development of new and existing product candidates under projected timelines.
• Need to comply with extensive and costly regulation by worldwide health authorities.
• Capacities and performance of suppliers and manufacturers and other third parties.
• Competitive position and development of competitors or industry.
• ONP-002 concussion candidate may face competition from biosimilars.
• Market opportunities for neurology product candidates may be smaller than believed.
• If manufacturers and suppliers fail to meet requirements, R&D may be adversely affected.
• Loss of key personnel or inability to hire successors could harm business.
• If product candidates are ineffective or harmful, unable to generate revenues.
• Might not be successful at acquiring, investing in, or integrating businesses, or entering joint ventures.
• Concussion and neurology R&D efforts dependent on intellectual property and biological materials licenses.
• May not be able to protect intellectual property, including trademarks.
• May be subject to claims challenging inventorship of patents.
• Lawsuits for infringing third-party intellectual property rights would be costly and time-consuming.
• Security breaches and disruptions to IT systems could compromise information.
• Clinical trials conducted outside the U.S. present additional risks.
• May be unable to obtain regulatory approval for product candidates.
• Delays or difficulties in patient enrollment in clinical trials.
• Approved products subject to ongoing regulatory review and healthcare laws.
• Employees, contractors, etc., may engage in misconduct.
• Approved products may fail to achieve broad adoption.
• Issuance of additional equity securities will result in dilution.
• Conversion of outstanding preferred stock will result in significant dilution.
• Certain corporate provisions may prevent a favorable change of control.
• Price and volume of common stock has been volatile.
• Requirements of being a public company may strain resources.
• Failure to maintain effective internal controls.
• Limited resources and decision to pause vaccine candidate may result in breach of contracts.
• Changes in patent law could diminish patent value.
• Inability to protect intellectual property rights globally.
• May incur costs of addressing cybersecurity incidents.
• Inability to achieve and maintain coverage and adequate reimbursement.
• May issue debt or debt securities convertible into equity, senior to common stock.
• As a smaller reporting company, reduced disclosure may make stock less attractive.

Future Outlook

The company anticipates launching Phase 2a clinical trials for ONP-002 in Australia in Q1 2026, followed by preparing for Phase 2b clinical trials and applying for an Investigational New Drug (IND) application with the FDA for a U.S. Phase 2b trial. Additional non-clinical studies are planned for 2026 as part of the IND submission strategy. Management expects research and development expenses to increase as clinical trial activities advance and manufacturing expands. The company will continue to seek strategic opportunities through business development, including alliances, licensing, and mergers and acquisitions, to enhance shareholder value.

Management Comments

• Management believes that the Company has sufficient liquidity to support its planned research and development activities and general corporate operations through the third quarter of 2026.
• Management evaluates its estimates and assumptions on an ongoing basis and adjusts them when facts and circumstances change.
• The Company expects research and development expenses to increase in future periods as clinical trial activities advance, and manufacturing of additional ONP-002 clinical material expands.
• We anticipate that our general and administrative expenses to increase, but be subject to variability.

Industry Context

StockSavvy.ai notes that Oragenics is targeting a significant unmet medical need in mild traumatic brain injury (mTBI or concussion), as there are currently no FDA-approved pharmacological therapies. The company's focus on intranasal delivery aligns with broader industry trends seeking non-invasive administration and rapid central nervous system exposure, potentially offering advantages over systemic administration for neurological conditions. The biopharmaceutical industry is characterized by intense competition and rapid technological change, with many larger, well-established companies having greater resources.

Comparison to Industry Standards

• The treatment of concussion represents a significant unmet medical need, as there are currently no FDA-approved pharmacological therapies specifically indicated for concussion, positioning ONP-002 in a potentially high-demand, low-competition therapeutic area if successful.
• The company faces competition from large, well-established pharmaceutical companies like Merck & Co., Inc., GlaxoSmithKline plc, CSL Ltd., Sanofi Pasteur, SA, Pfizer Inc., Johnson & Johnson, AstraZeneca, and Moderna, which possess significantly greater financial and technical resources, experience, and expertise across all stages of drug development and commercialization.
• Oragenics' strategy of seeking strategic alliances, licensing deals, and joint ventures is a common approach for smaller biopharmaceutical companies to leverage the resources and expertise of larger industry players, especially given the high capital intensity and risks of drug development.
• The company's decision to conduct Phase 1 and planned Phase 2a clinical trials in Australia leverages potential currency exchange advantages and R&D tax rebates, a strategy employed by some smaller biotechs to optimize development costs.

Management Changes

Corporate Governance

Legal Proceedings

• On October 16, 2025, the company and Ladenburg Thalmann & Co. Inc. executed a Settlement Agreement resolving all claims between the parties. The company agreed to pay $700,000, which was wired on October 17, 2025, in full satisfaction of a dispute over a $2.5 million fee related to the purchase of assets from Odyssey Health, Inc.

Stakeholder Impact

• Shareholders face significant dilution risk from future equity issuances and the conversion of preferred stock and warrants, especially given the anti-dilution provisions of Series H Preferred Stock. The company's going concern doubt and volatile stock price pose a risk of loss of investment, and no cash dividends are anticipated.
• Employees, particularly the small management team and key scientific personnel, are critical to the company's success, and their retention is supported by equity awards. The company's ability to attract additional qualified personnel is crucial for advancing product development.
• Potential customers (healthcare providers and patients) for ONP-002 face uncertainty regarding the product's eventual commercial availability, efficacy, safety, and reimbursement, as it is still in early clinical development.
• Suppliers and manufacturers, particularly the sole-source providers for ONP-002, are critical to the company's operations, and any disruption or failure on their part could severely impede development efforts.
• Creditors face risks due to the company's recurring losses and the auditor's 'going concern' qualification, although recent financing has temporarily improved liquidity.

Next Steps

• Launch Phase 2a clinical trials for ONP-002 in Australia in Q1 2026.
• Prepare for Phase 2b clinical trials.
• Apply for an Investigational New Drug (IND) application with the FDA for a U.S. Phase 2b trial.
• Conduct additional non-clinical studies in 2026 as part of the IND submission strategy.
• Seek strategic opportunities through business development, including alliances, licensing, joint ventures, collaborations, equity or debt-based investments, dispositions, mergers, and acquisitions.
• Identify and develop products for additional proprietary uses, utilizing the nasal delivery system for other brain-related medical issues, when funding allows.
• Pursue the development and acquisition of other product candidates.
• Seek partners to assist with the further development and clinical trials of ONP-002, potentially through government grants or from industry pharmaceutical companies.

Key Dates

Recommendation

The company faces significant financial distress, evidenced by recurring losses, a substantial accumulated deficit, and an explicit 'going concern' warning from its auditor. While the lead product candidate, ONP-002, has shown promising early-stage results, it is still in Phase 1/early Phase 2 development, with commercialization years away and requiring substantial additional capital. The recent capital raises, while providing short-term liquidity, have come with significant dilution to common shareholders, exacerbated by anti-dilution provisions that have already reduced the Series H Preferred Stock conversion price. The stock's high volatility and recent sharp decline further underscore the high risk. Given the precarious financial position, the long and uncertain path to market for its sole active product candidate, and the high dilution risk, a seasoned investor would likely recommend selling to avoid further potential losses.

Keywords

Biopharmaceutical, Neurology, Traumatic Brain Injury, Concussion, ONP-002, Clinical Trials, Drug Development, SEC Filing, OGEN, Preferred Stock, Warrants, Going Concern, Intellectual Property, NYSE American